GlassScriptPhysician profile
Brighton A Loveday
NPI 1871865071
$1,683.17
in general payments reported to CMS, 2019-2025
28 companies · $1,683 in 2025
The $1,683 reported for 2025 was more than what 92% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,683.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,683.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,683.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $251.14 | 2025 | Datroway, Imfinzi, Enhertu |
| Pfizer INC. | $211.47 | 2025 | |
| Abbvie INC. | $156.56 | 2025 | |
| Janssen Biotech, INC. | $154.28 | 2025 | Rybrevant, Erleada, Carvykti |
| Array Biopharma INC | $90.90 | 2025 | Lorbrena, Braftovi, Tukysa |
| Merck Sharp & Dohme LLC | $86.77 | 2025 | Keytruda, Welireg |
| Bayer Healthcare Pharmaceuticals INC. | $78.56 | 2025 | |
| Novartis Pharmaceuticals Corporation | $78.48 | 2025 | |
| Puma Biotechnology, INC. | $70.67 | 2025 | |
| Daiichi Sankyo INC. | $57.78 | 2025 | Enhertu, Datroway |
| Tersera Therapeutics LLC | $52.03 | 2025 | Zoladex, Quzyttir |
| Eisai INC. | $41.04 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $31.89 | 2025 | Lynozyfic |
| Fennec Pharmaceuticals, INC. | $30.28 | 2025 | Fyarro |
| Pharmaessentia USA Corporation | $29.47 | 2025 | Besremi |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $26.00 | 2025 | Fruzaqla |
| Stemline Therapeutics INC. | $24.62 | 2025 | Orserdu |
| Geron Corporation | $24.37 | 2025 | Rytelo |
| Menarini Silicon Biosystems, INC. | $22.94 | 2025 | |
| Beone Medicines USA, INC. | $21.18 | 2025 | Brukinsa |
| E.R. Squibb & Sons, L.L.C. | $20.07 | 2025 | Opdivo |
| Jazz Pharmaceuticals INC. | $19.87 | 2025 | |
| Tempus Ai, INC | $19.06 | 2025 | Xt Cdx |
| Syndax Pharmaceuticals, INC. | $17.84 | 2025 | Revuforj |
| Genzyme Corporation | $17.09 | 2025 | |
| Pharmacosmos Therapeutics INC. | $16.64 | 2025 | Monoferric |
| Coherus Oncology, INC. | $16.33 | 2025 | Loqtorzi |
| Novocure INC. | $15.84 | 2025 | Optune Lua (Novottf-200t) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brighton Loveday listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.